Starting intuition
ATPases of the AAA⁺ superfamily (ATPases Associated with diverse cellular Activities) are among the most ancient and best-conserved proteins in evolution — present in bacteria, archaea, and eukaryotes. They perform very diverse functions (disassembly of protein complexes, chromatin remodeling, vesicular transport, replication) but share a recognizable central ATPase architecture.
Druantia, an anti-phage defense system discovered in the Pasteur 2026 atlas, encodes MotA, a protein of the AAA⁺ superfamily involved in replication surveillance during phage infection. The precise mechanism remains to be characterized, but the AAA⁺ fold is immediately meaningful: it is one of the most druggable domains in the proteome, with several approved molecules targeting eukaryotic family members.
Among antiviral eukaryotic AAA⁺ ATPases of interest:
- VPS4: required for the budding of many enveloped viruses (HIV, Ebola, herpesvirus) via the ESCRT pathway
- p97/VCP: involved in the replication of several viruses; inhibited by CB-5083 in clinical trial
- RUVBL1/2: complex essential to influenza virus replication
Hypothesis
If the ATPase pocket of MotA (Druantia) shows structural similarity to the ATP pocket of human VPS4 or p97/VCP, then chemical scaffolds identified as MotA inhibitors could inform the design of inhibitors of antiviral eukaryotic AAA⁺ enzymes. The interest lies in having a bacterial “screenable” target (simpler manipulation, no eukaryotic cell toxicity during primary screening) as a proxy for testing the druggability of poorly accessible regions of eukaryotic ATPases.
This type of approach — using a bacterial structural enzyme to screen for a eukaryotic target without interfering toxicity — has already been used in kinase drug discovery (bacterial kinases as proxies for human kinases).
Key experimental questions
-
Structural alignment MotA vs. antiviral eukaryotic AAA⁺: VPS4 (PDB 7OFU, 7OFV), p97/VCP (PDB 5FTK), RUVBL1/2 (PDB 6FG5). Identify differences in activation loops (Arg-finger, sensor I/II) that determine selectivity.
-
Is MotA ATPase activity conditional? Some defensive bacterial AAA⁺ ATPases are auto-inhibited at rest and activated by a specific signal. Characterizing this activation mechanism conditions the relevance of screening.
-
Do known VPS4 or p97 inhibitors cross-react with MotA? Screening a library of approved compounds (FDA Approved Drug Library) against recombinant purifiable MotA would reveal hits with already-validated pharmacology.
-
Is there a clear cellular phenotype of VPS4 inhibition relevant to the Bactaegion context? Do the viruses targeted by Bactaegion (flaviviruses, enteroviruses, alphaviruses) use VPS4/ESCRT for their budding? Relevance varies with the viral envelope.
Limitations and risks
-
The AAA⁺ superfamily is vast and plastic: fold homologs can have very different enzymatic activities and binding modes. Structural homology does not guarantee chemical transferability.
-
p97/VCP is a validated but toxic target: its inhibition showed muscle adverse effects in clinical trials (CB-5083). Using MotA as a proxy would introduce an additional layer of necessary selectivity.
-
The Druantia mechanism has not yet been published in detail: the annotation “anti-phage defense system” in the 2026 atlas may not be accompanied by an experimental structure of MotA. The hypothesis rests on AlphaFold predictions and sequence homology.
Links to the Bactaegion scope
V1 family Druantia (Bernheim 2026 atlas, translational priority to be assessed). Potential modality: ATPase inhibitors. Aligned with NS-1 (corpus) and NS-2 (community evaluation). The druggability of AAA⁺ enzymes is established; the specific relevance of MotA as a proxy must be confirmed by structural alignment.